Xenon Pharmaceuticals: Leerink Partners cuts target price to $60 from $70
XENE•Leerink Partners cut its target price for Xenon Pharmaceuticals to $60 from $70.
Related News
A10 Networks schedules third-quarter 2026 results release, conference call
ATEN•
Xcel Brands, Paradium.AI partner to launch PetHelpful x Cesar Millan co-brand in 2027
XELB•
Viatris to acquire Pacira Biosciences in $1.65 billion deal
VTRS•
Hyperfine Q3 sales $6 million
HYPR•
Viatris agrees to buy Pacira BioSciences for $36.50 a share in cash, valuing deal at $1.65 billion
VTRS•